University of California awarded US CRISPR-Cas9 patent related to production of genetically modified cells.
M2 PHARMA-July 16, 2019-University of California awarded US CRISPR-Cas9 patent related to production of genetically modified cells
(C)2019 M2 COMMUNICATIONS
University of California (UC), University of Vienna and Dr Emmanuelle Charpentier reported on Tuesday the receipt of the new patent covering methods of producing a genetically modified cell through the introduction of the Cas9 protein, or a nucleic acid encoding the Cas9 protein, as well as a single molecule DNA-targeting RNA.
This US Patent and Trademark Office (USPTO) patent, which has been assigned the US 10,351,878, covers the use of this method in a cell, according to the company.
Along with previously issued patents, the new patent cover compositions and methods that allow for targeting and editing genes in any setting, including within plant, animal and human cells, as well as modulating transcription.
This issuance follows the award of seven other related patents in UC's steadily growing CRISPR-Cas9 portfolio plus seven more applications expected to issue as patents in the coming months, bringing its portfolio to 15 total patents.
The methods covered by the new patent, as well as the other methods claimed in UC's previously issued patents and those set to issue, were included among the CRISPR-Cas9 gene editing technology work.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 16, 2019|
|Previous Article:||Novian Health passes CE Mark for groundbreaking laser Novilase Breast Therapy.|
|Next Article:||New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies.|